<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01315470</url>
  </required_header>
  <id_info>
    <org_study_id>GCSF-HMO-CTIL</org_study_id>
    <nct_id>NCT01315470</nct_id>
  </id_info>
  <brief_title>Use of Granulocyte Colony-stimulating Factor for the Treatment of Recurrent Implantation Failure in IVF Patients</brief_title>
  <official_title>Phase 1 Study of the Use of Granulocyte Colony-stimulating Factor for the Treatment of Repeated Implantation Failure in IVF Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators use granulocyte colony-stimulating factor (GCSF) for the treatment of
      recurrent implantation failure in IVF patient with cause unknown or due to thin endometrium.
      Several studies showed that GCSF improves embryo development and implantation and increase
      pregnancy rate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators use granulocyte colony-stimulating factor (GCSF) for the treatment of
      repeated implantation failure (5 cycles) in IVF patient with cause unknown or due to thin
      endometrium. we intend to treat with GCSF during the IVF cycle if thin endometrium (&lt;6 mm) is
      the cause for the treatment failure, and during the implantation window if cause unknown.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">March 2013</completion_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pregnancy rate</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>endometrial thickness during IVF treatment</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endometrial thickness</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>neupogen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>no intervantion</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>neupogen administration for women with recurrent IVF failure</intervention_name>
    <description>neupogen 300 mcg - twice</description>
    <arm_group_label>neupogen</arm_group_label>
    <other_name>GCSF injection</other_name>
    <other_name>filgrastim</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. women after 5 failures in IVF cycles with cause unknown.

          2. women after 5 failures in IVF due to thin endometrium (&lt;6 mm) and unresponsive to
             estrogen supplements.

        Exclusion Criteria:

          1. history of hematology disease

          2. allergy to GCSF

          3. neutrophilia

          4. severe lower back pain

          5. liver dysfunction

          6. hyperuricemia

          7. a recent febrile disease or pneumonia

          8. rheumatoid arthritis 9. sickle cell disease-
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>einat zivi, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_contact>
    <last_name>einat zivi, MD</last_name>
    <phone>0508573943</phone>
    <email>zivi_e@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hadassah Ein Karem</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>einat zivi, MD</last_name>
      <phone>0508573943</phone>
      <email>zivi_e@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>einat zivi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein Karem</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>einat zivi, md</last_name>
      <email>zivi_e@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>einat zivi, md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/17512774</url>
    <description>3. GM-CSF regulation of embryo development and pregnancy. Robertson SA. Cytokine Growth Factor Rev. 2007 Jun-Aug;18(3-4):287-98</description>
  </link>
  <link>
    <url>http://www.pubmed.com</url>
    <description>3. GM-CSF regulation of embryo development and pregnancy. Robertson SA. Cytokine Growth Factor Rev. 2007 Jun-Aug;18(3-4):287-98</description>
  </link>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2011</study_first_submitted>
  <study_first_submitted_qc>March 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2011</study_first_posted>
  <last_update_submitted>March 23, 2011</last_update_submitted>
  <last_update_submitted_qc>March 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr Einat Zivi</name_title>
    <organization>organizational affiliation</organization>
  </responsible_party>
  <keyword>improving pregnancy rate and endometrial thickness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

